World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
43959
World Ranking
11986
National Ranking
648

Overview

Ralf Gutzmer is affiliated with Hannover Medical School in Germany. Their research primarily focuses on medicine, with a substantial number of publications in oncology and related biomedical fields.

The main fields of study for their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, the more specific subfields of study that characterize their research are:

  • Oncology
  • Molecular Biology
  • Dermatology
  • Epidemiology
  • Immunology

The major topics addressed in their work encompass:

  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • CAR-T cell therapy research
  • Nonmelanoma Skin Cancer Studies
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research

Ralf Gutzmer has contributed to several recent papers, notably including:

  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet

Their frequent coauthors reflect ongoing collaborations in the field and include:

  • Dirk Schadendorf
  • Carmen Loquai
  • Friedegund Meier
  • Selma Ugurel
  • Jessica C. Hassel

Scientific contributions by Ralf Gutzmer have been published frequently in several journals, highlighting the venues they often publish in:

  • European Journal of Cancer
  • JDDG Journal der Deutschen Dermatologischen Gesellschaft
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers

Best Publications

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    David Liu;David Liu;Bastian Schilling;Bastian Schilling;Derek Liu;Derek Liu;Antje Sucker

  • The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Nikhil Wagle;Nikhil Wagle;Antje Sucker;Daniel J. Treacy

  • Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

    Lars Hofmann;Andrea Forschner;Carmen Loquai;Simone M. Goldinger

  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

    Pertti Panula;Paul L. Chazot;Marlon Cowart;Ralf Gutzmer

  • Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.

    Ralf Gutzmer;Daniil Stroyakovskiy;Helen Gogas;Caroline Robert

  • Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

    Lisa Zimmer;Simone M. Goldinger;Lars Hofmann;Carmen Loquai

  • Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

    Benjamin Weide;Alexander Martens;Jessica C. Hassel;Carola Berking

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

    Paolo A. Ascierto;Michele Del Vecchio;Caroline Robert;Andrzej Mackiewicz

  • The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

    Caroline J. Voskens;Simone M. Goldinger;Carmen Loquai;Caroline Robert

  • Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Dirk Schadendorf;Paolo A Ascierto;Ana Arance

  • Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

    Michael R. Migden;Alexander Guminski;Ralf Gutzmer;Luc Dirix

  • Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

    Thomas K. Eigentler;Jessica C. Hassel;Carola Berking;Jens Aberle

  • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    David Liu;Bastian Schilling;Derek Liu;Antje Sucker

Frequent Co-Authors

Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Alexander Kapp
Alexander Kapp Hannover Medical School
Claus Garbe
Claus Garbe University of Tübingen
Thomas Werfel
Thomas Werfel Hannover Medical School
Axel Hauschild
Axel Hauschild Kiel University
Carola Berking
Carola Berking Ludwig-Maximilians-Universität München
Reinhard Dummer
Reinhard Dummer University of Zurich
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Jochen Utikal
Jochen Utikal German Cancer Research Center
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in a career in Medicine, but considering alternative or complementary healthcare paths? There are various online degree programs in the health sector that offer flexibility, affordability, and strong career prospects.

For those who aspire to leadership roles in healthcare settings, pursuing a most affordable mha programs (Master’s in Healthcare Administration) can open doors to management positions in hospitals, clinics, and allied healthcare organizations.

Nurses aiming to advance their clinical expertise may consider most affordable dnp programs (Doctor of Nursing Practice), which emphasize leadership, policy, and evidence-based practice.

If pharmacy sparks your interest, you can now complete much of your training through pharmacy degree online programs, preparing you for pharmaceutical care and research roles.

For those more inclined toward the data and technology side of healthcare, exploring rhit programs online (Registered Health Information Technician) can lead to careers in managing patient data, compliance, and information security.

These online programs provide diverse pathways for making a meaningful impact in healthcare, often at a lower cost and greater convenience compared to traditional on-campus degrees.

Best Scientists Citing Ralf Gutzmer

Trending Scientists